Expressions of CK-19, NF-κB, E-cadherin,-βcatenin and EGFR as diagnostic and prognostic markers by immunohistochemical analysis in thyroid carcinoma

Kruttibas Sethi, Siddik Sarkar, Subhasis Das, Shashi Rajput, Abhijit Mazumder, Bhaskar Roy, Susmita Patra, Biswanarayan Mohanty, Adel K El-Naggar, Mahitosh Mandal

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Immunohistochemical markers have been proposed for thyroid cancer diagnosis and prognostic studies. Immunohistochemical analysis of CK-19, NF-κB, β-catenin, E-cadherin and EGFR were done to evaluate their diagnostic and prognostic efficiencies in eighty eight cancer specimen (PTC-52, FTC-16, benign nodule- 12 and MNG-8). CK-19 was positive in 91% (62/68) DTC, 98% (51/52) PTC, 69% (11/16) FTC and 15% (3/20) benign thyroid nodules. NF-κB was expressed 93% (63/68) DTC, in 96% (50/52) PTC, 81% (11/16) FTC and 15% (3/20) benign thyroid nodules. Both CK- 19 and NF-κB were significantly differentiated DTC, PTC and FTC from benign thyroid nodule (p<0.0001) with diagnostic accuracy of 89.74%, 94.4% and 77.4% for CK-19 and 91.0%, 90.5% and 83.5% respectively for NF-κB. Though CK-19 and NF-κB were equally sensitive but CK-19 was most specific in the diagnosis of DTC and PTC. The diagnostic accuracy of β-catenin was 96% and 94% and accuracy of E-cadherin was 90.1% and 93.9% for the diagnosis of metastatic PTC and FTC respectively. EGFR showed 90% (18/20) of metastatic PTC (p<0.0001) and sensitivity, specificity and accuracy were 90%, 71.8% and 78.85% respectively. CK-19 and NF-κB were accurately diagnosed in DTC, PTC and FTC whereas, NF-κB, E-cadherin, β-catenin and EGFR were strongly expressed in invasive papillary thyroid cancers and FTC, thus can be important diagnostic and prognostic marker for FTC and metastatic PTC. This may be concluded that immunohistochemical expression of panel of markers CK-19, NF-κB, E-cadherin, β-catenin and EGFR can be useful in diagnosis and prognosis of DTC.

Original languageEnglish (US)
Pages (from-to)187-199
Number of pages13
JournalJournal of Experimental Therapeutics and Oncology
Volume9
Issue number3
StatePublished - Dec 29 2011

Fingerprint

Catenins
Factor IX
Cadherins
Thyroid Neoplasms
Thyroid Nodule
Sensitivity and Specificity

Keywords

  • β-catenin
  • Cytokeratin-19 (CK-19)
  • Differentiated thyroid carcinoma (DTC)
  • E-cadherin
  • Follicular thyroid carcinoma (FTC)
  • Nuclear factor-kappa B (NF-κB)
  • Papillary thyroid carcinoma (PTC)

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Cancer Research

Cite this

Expressions of CK-19, NF-κB, E-cadherin,-βcatenin and EGFR as diagnostic and prognostic markers by immunohistochemical analysis in thyroid carcinoma. / Sethi, Kruttibas; Sarkar, Siddik; Das, Subhasis; Rajput, Shashi; Mazumder, Abhijit; Roy, Bhaskar; Patra, Susmita; Mohanty, Biswanarayan; El-Naggar, Adel K; Mandal, Mahitosh.

In: Journal of Experimental Therapeutics and Oncology, Vol. 9, No. 3, 29.12.2011, p. 187-199.

Research output: Contribution to journalArticle

Sethi, Kruttibas ; Sarkar, Siddik ; Das, Subhasis ; Rajput, Shashi ; Mazumder, Abhijit ; Roy, Bhaskar ; Patra, Susmita ; Mohanty, Biswanarayan ; El-Naggar, Adel K ; Mandal, Mahitosh. / Expressions of CK-19, NF-κB, E-cadherin,-βcatenin and EGFR as diagnostic and prognostic markers by immunohistochemical analysis in thyroid carcinoma. In: Journal of Experimental Therapeutics and Oncology. 2011 ; Vol. 9, No. 3. pp. 187-199.
@article{d03482247e844e33a1d86ae3c7ed020e,
title = "Expressions of CK-19, NF-κB, E-cadherin,-βcatenin and EGFR as diagnostic and prognostic markers by immunohistochemical analysis in thyroid carcinoma",
abstract = "Immunohistochemical markers have been proposed for thyroid cancer diagnosis and prognostic studies. Immunohistochemical analysis of CK-19, NF-κB, β-catenin, E-cadherin and EGFR were done to evaluate their diagnostic and prognostic efficiencies in eighty eight cancer specimen (PTC-52, FTC-16, benign nodule- 12 and MNG-8). CK-19 was positive in 91{\%} (62/68) DTC, 98{\%} (51/52) PTC, 69{\%} (11/16) FTC and 15{\%} (3/20) benign thyroid nodules. NF-κB was expressed 93{\%} (63/68) DTC, in 96{\%} (50/52) PTC, 81{\%} (11/16) FTC and 15{\%} (3/20) benign thyroid nodules. Both CK- 19 and NF-κB were significantly differentiated DTC, PTC and FTC from benign thyroid nodule (p<0.0001) with diagnostic accuracy of 89.74{\%}, 94.4{\%} and 77.4{\%} for CK-19 and 91.0{\%}, 90.5{\%} and 83.5{\%} respectively for NF-κB. Though CK-19 and NF-κB were equally sensitive but CK-19 was most specific in the diagnosis of DTC and PTC. The diagnostic accuracy of β-catenin was 96{\%} and 94{\%} and accuracy of E-cadherin was 90.1{\%} and 93.9{\%} for the diagnosis of metastatic PTC and FTC respectively. EGFR showed 90{\%} (18/20) of metastatic PTC (p<0.0001) and sensitivity, specificity and accuracy were 90{\%}, 71.8{\%} and 78.85{\%} respectively. CK-19 and NF-κB were accurately diagnosed in DTC, PTC and FTC whereas, NF-κB, E-cadherin, β-catenin and EGFR were strongly expressed in invasive papillary thyroid cancers and FTC, thus can be important diagnostic and prognostic marker for FTC and metastatic PTC. This may be concluded that immunohistochemical expression of panel of markers CK-19, NF-κB, E-cadherin, β-catenin and EGFR can be useful in diagnosis and prognosis of DTC.",
keywords = "β-catenin, Cytokeratin-19 (CK-19), Differentiated thyroid carcinoma (DTC), E-cadherin, Follicular thyroid carcinoma (FTC), Nuclear factor-kappa B (NF-κB), Papillary thyroid carcinoma (PTC)",
author = "Kruttibas Sethi and Siddik Sarkar and Subhasis Das and Shashi Rajput and Abhijit Mazumder and Bhaskar Roy and Susmita Patra and Biswanarayan Mohanty and El-Naggar, {Adel K} and Mahitosh Mandal",
year = "2011",
month = "12",
day = "29",
language = "English (US)",
volume = "9",
pages = "187--199",
journal = "Journal of Experimental Therapeutics and Oncology",
issn = "1359-4117",
publisher = "Old City Publishing",
number = "3",

}

TY - JOUR

T1 - Expressions of CK-19, NF-κB, E-cadherin,-βcatenin and EGFR as diagnostic and prognostic markers by immunohistochemical analysis in thyroid carcinoma

AU - Sethi, Kruttibas

AU - Sarkar, Siddik

AU - Das, Subhasis

AU - Rajput, Shashi

AU - Mazumder, Abhijit

AU - Roy, Bhaskar

AU - Patra, Susmita

AU - Mohanty, Biswanarayan

AU - El-Naggar, Adel K

AU - Mandal, Mahitosh

PY - 2011/12/29

Y1 - 2011/12/29

N2 - Immunohistochemical markers have been proposed for thyroid cancer diagnosis and prognostic studies. Immunohistochemical analysis of CK-19, NF-κB, β-catenin, E-cadherin and EGFR were done to evaluate their diagnostic and prognostic efficiencies in eighty eight cancer specimen (PTC-52, FTC-16, benign nodule- 12 and MNG-8). CK-19 was positive in 91% (62/68) DTC, 98% (51/52) PTC, 69% (11/16) FTC and 15% (3/20) benign thyroid nodules. NF-κB was expressed 93% (63/68) DTC, in 96% (50/52) PTC, 81% (11/16) FTC and 15% (3/20) benign thyroid nodules. Both CK- 19 and NF-κB were significantly differentiated DTC, PTC and FTC from benign thyroid nodule (p<0.0001) with diagnostic accuracy of 89.74%, 94.4% and 77.4% for CK-19 and 91.0%, 90.5% and 83.5% respectively for NF-κB. Though CK-19 and NF-κB were equally sensitive but CK-19 was most specific in the diagnosis of DTC and PTC. The diagnostic accuracy of β-catenin was 96% and 94% and accuracy of E-cadherin was 90.1% and 93.9% for the diagnosis of metastatic PTC and FTC respectively. EGFR showed 90% (18/20) of metastatic PTC (p<0.0001) and sensitivity, specificity and accuracy were 90%, 71.8% and 78.85% respectively. CK-19 and NF-κB were accurately diagnosed in DTC, PTC and FTC whereas, NF-κB, E-cadherin, β-catenin and EGFR were strongly expressed in invasive papillary thyroid cancers and FTC, thus can be important diagnostic and prognostic marker for FTC and metastatic PTC. This may be concluded that immunohistochemical expression of panel of markers CK-19, NF-κB, E-cadherin, β-catenin and EGFR can be useful in diagnosis and prognosis of DTC.

AB - Immunohistochemical markers have been proposed for thyroid cancer diagnosis and prognostic studies. Immunohistochemical analysis of CK-19, NF-κB, β-catenin, E-cadherin and EGFR were done to evaluate their diagnostic and prognostic efficiencies in eighty eight cancer specimen (PTC-52, FTC-16, benign nodule- 12 and MNG-8). CK-19 was positive in 91% (62/68) DTC, 98% (51/52) PTC, 69% (11/16) FTC and 15% (3/20) benign thyroid nodules. NF-κB was expressed 93% (63/68) DTC, in 96% (50/52) PTC, 81% (11/16) FTC and 15% (3/20) benign thyroid nodules. Both CK- 19 and NF-κB were significantly differentiated DTC, PTC and FTC from benign thyroid nodule (p<0.0001) with diagnostic accuracy of 89.74%, 94.4% and 77.4% for CK-19 and 91.0%, 90.5% and 83.5% respectively for NF-κB. Though CK-19 and NF-κB were equally sensitive but CK-19 was most specific in the diagnosis of DTC and PTC. The diagnostic accuracy of β-catenin was 96% and 94% and accuracy of E-cadherin was 90.1% and 93.9% for the diagnosis of metastatic PTC and FTC respectively. EGFR showed 90% (18/20) of metastatic PTC (p<0.0001) and sensitivity, specificity and accuracy were 90%, 71.8% and 78.85% respectively. CK-19 and NF-κB were accurately diagnosed in DTC, PTC and FTC whereas, NF-κB, E-cadherin, β-catenin and EGFR were strongly expressed in invasive papillary thyroid cancers and FTC, thus can be important diagnostic and prognostic marker for FTC and metastatic PTC. This may be concluded that immunohistochemical expression of panel of markers CK-19, NF-κB, E-cadherin, β-catenin and EGFR can be useful in diagnosis and prognosis of DTC.

KW - β-catenin

KW - Cytokeratin-19 (CK-19)

KW - Differentiated thyroid carcinoma (DTC)

KW - E-cadherin

KW - Follicular thyroid carcinoma (FTC)

KW - Nuclear factor-kappa B (NF-κB)

KW - Papillary thyroid carcinoma (PTC)

UR - http://www.scopus.com/inward/record.url?scp=84455171494&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84455171494&partnerID=8YFLogxK

M3 - Article

C2 - 22070050

AN - SCOPUS:84455171494

VL - 9

SP - 187

EP - 199

JO - Journal of Experimental Therapeutics and Oncology

JF - Journal of Experimental Therapeutics and Oncology

SN - 1359-4117

IS - 3

ER -